Shares of Zoetis Inc. (NYSE:ZTS) have received an average recommendation of “Buy” from the nineteen analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $65.12.

A number of research firms have recently weighed in on ZTS. Cantor Fitzgerald reiterated a “buy” rating and issued a $75.00 price objective on shares of Zoetis in a research note on Wednesday, September 6th. Hilliard Lyons initiated coverage on shares of Zoetis in a research report on Tuesday, June 20th. They set a “buy” rating and a $77.00 price target on the stock. Zacks Investment Research lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $62.00 price target on shares of Zoetis in a research report on Monday, August 7th. Finally, Piper Jaffray Companies set a $73.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Friday, August 25th.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/zoetis-inc-zts-given-average-rating-of-buy-by-brokerages/1585739.html.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.53. The firm had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.49 earnings per share.

Several institutional investors have recently added to or reduced their stakes in the company. Toronto Dominion Bank raised its stake in shares of Zoetis by 25.4% in the 2nd quarter. Toronto Dominion Bank now owns 166,276 shares of the company’s stock valued at $10,370,000 after acquiring an additional 33,718 shares during the period. Advisory Services Network LLC raised its stake in shares of Zoetis by 82.4% in the 2nd quarter. Advisory Services Network LLC now owns 3,829 shares of the company’s stock valued at $239,000 after acquiring an additional 1,730 shares during the period. Dynamic Technology Lab Private Ltd raised its stake in shares of Zoetis by 7.3% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 5,901 shares of the company’s stock valued at $368,000 after acquiring an additional 401 shares during the period. Public Employees Retirement System of Ohio raised its stake in shares of Zoetis by 3.9% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 237,680 shares of the company’s stock valued at $14,826,000 after acquiring an additional 9,028 shares during the period. Finally, Covington Capital Management purchased a new stake in shares of Zoetis in the 2nd quarter valued at approximately $831,000. 93.20% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.